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1. Introduction 
The global burden of epilepsy is substantial, especially in the developing regions of the 
world where treatments are less accessible (de Boer et al., 2008). One contribution to the 
overall disease burden is the higher prevalence of comorbidities among patients with 
epilepsy, compared to the general population. These include psychological comorbidities, 
such as depression, which have been associated with epilepsy, both before and after 
epilepsy diagnosis (Hesdorffer et al., 2005). Other neurological diseases such as migraine 
have also been associated with epilepsy (Ottman & Lipton, 1994). 
Two database studies were utilised to assess the overall comorbidity profiles of patients 
with epilepsy and matched controls without epilepsy. The analyses allow for comparisons 
between the relative prevalence estimates of comorbidities within populations captured 
through electronic health data sources. The US Impact National Managed Care 
Benchmark Database (IHCIS) is an insurance claims database provided by Ingenix, Eden 
Prairie, MN, and the UK General Practice Research Database (GPRD) Gold contains 
electronic medical records and is managed by the Medicines and Healthcare products 
Regulatory Agency. 
The IHCIS database contains medical (inpatient, outpatient, physician, and ancillary) and 
pharmacy claims from a national sample of 46 managed care health plans covering 
approximately 93 million lives over the period 1997 to 2009.  
The GPRD Gold is the world's largest computerised database of anonymised longitudinal 
medical records from primary care (Jick et al., 2003). The data are drawn from the computer 
systems used by general practitioners (GPs) to maintain the clinical records within their 
practices, and contain all records that primary care deemed relevant to patient care. 
Currently, data are available from 561 "research standard" general practices throughout the 
UK, providing information from 4.0 million currently registered patients (c. 9.0 million in 
total). 
The objectives of the current analyses were: (1) to calculate the prevalence of epilepsy 
diagnosis in a US and a UK electronic health record system, stratified by gender and age 
www.intechopen.com
 
Novel Treatment of Epilepsy                          
 
160 
category; (2) to describe and compare the prevalence of co-morbidities, in epilepsy patients 
and matched controls without any record of epilepsy; and (3) to describe the prevalence of 
medication use by epilepsy patients during a one-year period of observation. 
2. Methods 
This study was a case-control study comparing comorbidities between patients with 
epilepsy and matched controls without epilepsy, and a descriptive study reporting 
medication use among patients with epilepsy. 
2.1 Patient population 
2.1.1 Case selection 
The definitions of active epilepsy reflected the structure of the databases and how medical 
and pharmacy data are captured: 
In IHCIS, epilepsy cases were identified based on at least two records of epilepsy on or 
before the index date and with 30 days or more between the first and last record of epilepsy. 
At least one of the records of epilepsy had to be recorded within the lead-in period to 
identify individuals with recently active epilepsy. Epilepsy was defined as the ICD-9 code 
345*, with * indicating all terms under this hierarchy. AED treatment was not part of the 
case definition of epilepsy in the IHCIS in order to capture epilepsy patients in the claims 
database that may not have pharmacy benefits. Also, disease diagnoses are recorded on a 
regular basis in the insurance claims, therefore a repeat diagnosis could be used to confirm 
the epilepsy diagnosis. 
In the GPRD, epilepsy cases were identified as those with one epilepsy diagnosis (READ) 
code on or before the index date. The relevant GPRD medical codes were identified and 
reviewed by a clinician. Within the GPRD, active epilepsy cases were required to have at 
least 2 anti-epileptic drug (AED) prescriptions within -3 and +6 months of any epilepsy 
diagnosis code AND at least 1 AED prescription within the lead-in or analysis period. In the 
GPRD, a diagnosis is often recorded only one time on the database therefore the 
medications were used as a proxy to confirm the diagnosis and that the diagnosis was still 
active near the time of the index date. 
Full definitions of index date, analysis and lead-in periods are provided in Section Data 
Analysis. 
2.1.2 Control selection 
Controls were matched to cases at a ratio of 1:1 by: gender, exact year of birth, duration of 
prior continuous enrolment in the database (from index date) by the following categories (1-
<2 years, 2-<3 years, 3-<4 years, 4 or more years). 
For IHCIS specifically, controls were also matched on pharmacy benefits throughout the full 
analysis period (Yes/No), Mental Health benefits on the index date (Yes/No/Partial), and 
Provider/Plan Type (on the index date). 
For GPRD specifically, the controls were also matched by General Practice site. 
2.2 Data analysis 
The analysis period was defined as the 12 month period from 01/Jan/2009 to 31/Dec/2009, 
inclusive. The first day of the analysis period (01/Jan/2009) was assigned as the "index 
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date" for cases and their matched controls. The pre-analysis lead-in period was defined as 
the 12 month period from 01/Jan/2008 to 31/Dec/2008, inclusive. Thus, the study inclusion 
period contains all time from 01/Jan/2008 to 31/Dec/2009, inclusive. 
A base population was defined containing all patients eligible for this study. This was the 
denominator for calculations of the population prevalence of epilepsy. All cases and 
controls were selected from this population. 
For inclusion in the base population, a patient must have been:  
• registered on the database for the full lead-in period to allow the identification of 
existing epilepsy patients.  
• registered on the database for the full analysis period to allow the characterisation of 
patients' current medication and comorbidities. 
• aged between 0 and 120 years inclusive, on the index date 
For the IHCIS, the analyses of medication use were restricted to those cases with full 
pharmacy benefits throughout the analysis period and no gaps in pharmacy benefit greater 
than one day during the analysis period. 
2.2.1 Analysis 1: prevalence of epilepsy 
The prevalence of epilepsy on the index date was determined, by gender and age 
category, as appropriate. The denominator was taken as all patients within the base 
population. In IHCIS, the numerator was calculated as all patients (within the 
denominator population) with two or more records of epilepsy, and 30 days or more 
between the first and last record of epilepsy. In GPRD, the numerator was calculated as all 
patients (within the denominator population) with an epilepsy diagnosis prior to the 
index date, and at least 2 anti-epileptic drug (AED) prescriptions within -3 and +6 months 
of any epilepsy diagnosis code AND at least 1 AED prescription within the lead-in or 
analysis period. For both databases, at least one of the diagnoses must be on, or before, 
the index date. 
2.2.2 Analysis 2: listing of comorbidities in epilepsy patients 
The prevalence of comorbidities within the epilepsy and control populations was 
determined. A patient was considered to have a comorbidity if they had one or more 
records of this condition within the time period being considered. Prevalence of comorbid 
disease in the epilepsy population was calculated as the number of epilepsy cases with a 
record of the disease (within the time periods defined below) divided by the total number of 
epilepsy cases. Prevalence of comorbid diseases in the controls were similarly calculated.  
Analyses were repeated for two time periods, (1) the analysis period and (2) the analysis 
period, and any time before, within the period of continuous enrollment. 
In GPRD, the comorbidities are listed as defined by disease headings which were based on 
the Meddra Dictionary and were reviewed by clinicians. A Read/MedDRA (version 13.0) 
mapping was created using the available Read/MedDRA (version 6) dictionary and the 
2010-AB release of the Unified Medical Language System (UMLS). Approximately 41% of 
events were not mapped, but many of the events remaining unmapped were not of clinical 
significance. Some of these were mapped by further review of terms. 
In IHCIS, comorbidities are reported by Clinical Classifications Software (CCS) level 4 
(HCUP, 2011). 
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In addition, there were a number of conditions previously associated with epilepsy that 
were specifically explored including: depression, anxiety, bipolar disorder, suicidality, and 
migraine. These conditions were defined by clinician-reviewed coding lists using GPRD 
GOLD READ medical codes or ICD-9 codes for IHCIS. 
In GPRD, medications are listed as defined by British National formulary (BNF) class, and in 
IHCIS by Universal System Classification (USC) Fourth Level. The USC is a categorization 
system, developed by IMS, to resolve a need for therapeutic classification of pharmaceutical 
products; the USC is widely accepted in North America as the standard for pharmaceutical 
product classification. 
2.2.3 Analysis 3: comparative analyses of the occurrence co-morbidities 
The relative prevalence of co-morbidities in epilepsy cases and matched controls was 
assessed. Unstratified matched analyses were conducted via conditional logistic regression 
using the SAS Proc PHREG procedure. Stratified analyses were conducted via the Fisher 
Exact tests using the SAS Proc FREQ procedure. Odds ratios (ORs) and 95% confidence 
intervals are presented (Note: p-values are not presented). Since these were exploratory 
(rather than hypothesis testing) analyses, and sample sizes are not based on statistical 
considerations, there was no adjustment for multiple testing. ORs are only presented where 
there were at least five patients in both the case and control populations with a record of the 
comorbidity within the time period being considered. Results are presented for the 25 most 
frequent comorbidities amongst cases, and for the 25 highest ORs comparing cases and 
controls. 
2.2.4 Analysis 4: listing of prescribed medications used by epilepsy cases during a 
one-year period of observation 
The prevalence of drug use within the analysis period is presented for the epilepsy 
population. A patient was considered to be using the drug of interest if they were issued a 
prescription during the analysis period. The prevalence of drug use was calculated as the 
number of eligible cases with a record of use within the analysis period divided by the total 
number of eligible cases. Results are presented for cases only, and reported at Universal 
System Classification Fourth Level. 
3. Results 
There were 27,328 active epilepsy cases and 27,328 matched controls identified in the UK 
GPRD, and 83,045 active epilepsy cases and 83,045 controls identified from the IHCIS. 
Active epilepsy in GPRD was defined if a patient diagnosed with epilepsy had at least one 
AED prescription within the one-year lead-in or one-year analysis period. Active epilepsy in 
the IHCIS was defined if the patient had at least one diagnosis code within the lead-in or 
analysis period. The overall prevalence of active epilepsy was 0.8% in GPRD and 0.5% in 
IHCIS. The prevalence in GPRD increased with age and was highest in the age group 65 
years and older. The prevalence was similar across the age groups in IHCIS with a peak of 
0.5% in the age group 45 to 64 years. 
The studies within the US claims database (IHCIS) and UK general practice database 
(GPRD) compared the prevalence of a range of psychiatric conditions including anxiety, 
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bipolar disorder, depression, schizophrenia/psychosis and suicidality (Table 1&Table 2). 
These psychiatric conditions were significantly more common in epilepsy cases than in 
controls (OR > 1.0, and lower bound of 95% CI excluding 1.0). The highest ORs were for 
suicidality, bipolar disorder and schizophrenia. Migraine was also included in the 
analyses, and it was significantly more common among cases than controls for the time 
period during or before analysis period. However, the association was not significant for 
the analysis period only in GPRD, and the associations were stronger in IHCIS than 
GPRD. Given the chronic nature of these conditions the prevalence was considered both 
during and prior to the analysis period (i.e. the latter period represented the patients’ 
medical histories).  
 
 
 
 
 
 
 
 
 
 
Fig. 1. The prevalence of active epilepsy per 100 persons on 1st January 2009 in the GPRD 
and IHCIS databases, stratified by age and sex 
The top 25 most common diagnosed comorbidities among cases are reported for within the 
analysis period (Table 3 & Table 7) and within the analysis period or before (Table 4 & Table 
8), for GPRD and IHCIS respectively. As expected, the medical condition headings related to 
epilepsy, seizures and convulsions were at the top of the lists. Other conditions included 
respiratory infections, skin conditions, and hypertension. The latter conditions were also 
common in controls. 
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The top 25 diagnosed comorbidities with the highest ORs comparing cases to controls were 
reported for the analysis period (Table 5 & Table 9) and within the analysis period or before 
(Table 6 & Table 10), for GPRD and IHCIS respectively. These listings can be considered for 
generating hypotheses about the associations between epilepsy and other conditions, 
though temporality cannot be established.  
In the GPRD, mental retardation had a high OR of 24.9 (95%CI: 12.3-50.4) during the 
analysis period. During the GPRD analysis period, the conditions with the highest ORs 
included many neurological conditions and behaviour and socialisation disturbances (Table 
5). In the GPRD analysis period or ever before, the conditions with the highest ORs also 
included neurological and developmental conditions, and the highest ORs were 50.7 
(95%CI: 28.0-92.1) for “Cerebral disorders congenital”, 38.1 (95%CI: 20.9-69.3) for 
“Congenital and peripartum cerebral disorders”, and 33.9 (95%CI: 16.8-68.4) for “Neonatal 
neurological system disorders NEC” (Table 6).  
The highest OR in the IHCIS was for intellectual disabilities, 143.1 (95%CI: 84.6-241.9) 
during the analysis period, and 79.8 (95%CI: 60.1-106.1) during the analysis period or ever 
before. The other conditions with high ORs included neurological disorders, 
cerebrovascular disease, developmental and learning disorders, and mental disorders (Table 
9 & Table 10). 
Medication use was reported for the analysis year, 2009, for epilepsy cases only (N=27,328 
GPRD; N= 46,912 IHCIS). For IHCIS, only individuals with full pharmacy benefits 
throughout the year 2009 were included in medication analyses. The proportion of patients 
using anti-depressants and anti-epileptic drugs were reported using clinician-reviewed drug 
coding lists (Table 11 & Table 13). In the GPRD, 97% of the epilepsy cases had a prescription 
for an anti-epileptic drug in the analysis period, as expected since AED use either in the 
lead-in or analysis period was a requirement of the case definition (3% of cases only had 
AED use in the lead-in period). Eighteen percent of cases had a prescription for anti-
depressants in the one-year analysis period. In the IHCIS, 76% of epilepsy patients had a 
prescription for an AED, and 22% for anti-depressants in 2009. The 24% of epilepsy cases 
who did not have an AED in the analysis period may either not have had pharmacy benefit, 
or they were not prescribed an AED in that time period. However, the relative proportions 
of patients using each type of AED are of interest, and there are differences in the AED use 
between the UK GPRD and US IHCIS. Two of the older AEDs, valproate (34%) and 
carbamazepine (32%) were the most frequently used AEDs among epilepsy patients in the 
GPRD, followed by lamotrigine (18%) and phenytoin (17%).  Lamotrigine (15%) and 
phenytoin (15%) were the most commonly used AEDs in the IHCIS in 2009, followed by 
carbamazepine (12%) and topiramate (9%). 
The top 25 most commonly prescribed medication categories in a one year time period, 2009, 
are reported for GPRD (Table 12) and IHCIS (Table 14). As in (Table 11), drugs classified as 
“Control of Epilepsy” were the most commonly prescribed in GPRD (97.3%). Other common 
medications were neuropathic pain (52.3%), non-opioid analgesics (39.7%), anti-manic drugs 
(32.4%), non-steroidal anti-inflammatory drugs (30.2%), opioid analgesics (23.8%), broad 
spectrum penicillins (21.1%), and statins (20.2%). In the IHCIS, 74% of epilepsy patients had 
a prescription in the “Seizure disorders” drug category during 2009. The other frequently 
prescribed medications were codeine (23%), extended spectrum macroli (19%), 
benzodiazepines (17%), and selective serotonin reuptake inhibitors (SSRI, 15%). 
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 GPRD IHCIS 
Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls 
Odds Ratio 
(95% CI) 
Number 
Cases 
Percent 
Cases 
Anxiety 750 2.74 677 2.48 1.1 (1, 1.2) 9354 11.26 
Bipolar Disorder 26 0.1 7 0.03 3.7 (1.6, 8.6) 2029 2.44 
Depression 1207 4.42 1034 3.78 1.2 (1.1, 1.3) 9696 11.68 
Migraine 188 0.69 173 0.63 1.1 (0.9, 1.3) 5806 6.99 
Schizophrenia 
(GPRD)/ 
Psychosis  
(IHCIS) 
20 0.07 5 0.02 4.0 (1.5, 10.7) 2215 2.67 
Suicidality 76 0.28 20 0.07 3.8 (2.3, 6.2) 1389 1.67 
w
w
w
.intechopen.com
  
S
u
icid
ality
 =
 S
u
icid
e attem
p
ts, p
ro
b
ab
le su
icid
e attem
p
ts an
d
 su
icid
al id
eatio
n
 
C
I=
 C
o
n
fid
en
ce in
terv
al; G
P
R
D
=
 G
en
eral P
ractice R
esearch
 D
atab
ase; IH
C
IS
=
 In
teg
rated
 H
ealth
care 
In
fo
rm
atio
n
 S
erv
ices 
T
ab
le 2. P
rev
alen
ce an
d
 o
d
d
s ratio
s fo
r th
e co
m
o
rb
id
ities o
f in
terest co
m
p
arin
g
 cases 
(N
=
27,328 G
P
R
D
; N
=
83,045 IH
C
IS
) an
d
 co
n
tro
ls (N
=
27,328 G
P
R
D
; N
=
83,045 IH
C
IS
) d
u
rin
g
 
o
r ev
er b
efo
re th
e an
aly
sis p
erio
d
 
 GPRD IHCIS 
Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls 
Odds Ratio 
(95% CI) 
Number 
Cases 
Percent 
Cases 
Anxiety 5858 21.44 4544 16.63 1.4 (1.3, 1.5) 21214 25.55 
Bipolar 
Disorder 
217 0.79 97 0.35 2.3 (1.8, 2.9) 3829 4.61 
Depression 7988 29.23 6196 22.67 1.5 (1.4, 1.5) 19762 23.8 
Migraine 2378 8.70 1841 6.74 1.3 (1.3, 1.4) 13557 16.32 
Schizophrenia 
(GPRD)/  
Psychosis  
(IHCIS) 
299 1.09 108 0.40 2.8 (2.3, 3.6) 7299 8.79 
Suicidality 1011 3.70 378 1.38 2.8 (2.5, 3.1) 4877 5.87 
w
w
w
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls
Social issues 4276 15.65 3527 12.91 
Musculoskeletal and connective tissue pain and discomfort 3751 13.73 3196 11.69 
Coughing and associated symptoms 3607 13.20 2728 9.98 
Upper respiratory tract infections NEC 3112 11.39 2693 9.85 
Upper respiratory tract infections 3111 11.38 2693 9.85 
Joint related signs and symptoms 2826 10.34 2405 8.80 
Seizures and seizure disorders NEC 2638 9.65 11 0.04 
Dietary and nutritional therapies 2441 8.93 1977 7.23 
General signs and symptoms NEC 2313 8.46 1482 5.42 
Reproductive organ and breast histopathology procedures 2262 8.28 2499 9.14 
Lower respiratory tract and lung infections 1946 7.12 1138 4.16 
Lower respiratory tract infections NEC 1936 7.08 1125 4.12 
Non-site specific injuries NEC 1548 5.66 876 3.21 
Pain and discomfort NEC 1450 5.31 1116 4.08 
Bronchospasm and obstruction 1444 5.28 1128 4.13 
Neurological signs and symptoms NEC 1429 5.23 764 2.80 
Dermatitis and eczema 1400 5.12 1076 3.94 
Urinary tract infections 1349 4.94 754 2.76 
Asthenic conditions 1343 4.91 862 3.15 
Gastrointestinal and abdominal pains (excl oral and throat) 1318 4.82 1092 4,00 
Vascular hypertensive disorders NEC 1207 4.42 1381 5.05 
Oral soft tissue infections 1174 4.30 973 3.56 
Bladder and urethral symptoms 1135 4.15 683 2.50 
Gastrointestinal atonic and hypomotility disorders NEC 1128 4.13 598 2.19 
Headaches NEC 1079 3.95 751 2.75 
w
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls
Seizures and seizure disorders NEC 26225 95.96 279 1.02 
Social issues 17790 65.10 16830 61.59 
Upper respiratory tract infections NEC 16529 60.48 15504 56.73 
Upper respiratory tract infections 16529 60.48 15504 56.73 
Musculoskeletal and connective tissue pain and 
discomfort 
15299 55.98 14339 52.47 
Coughing and associated symptoms 13657 49.97 11438 41.85 
General signs and symptoms NEC 12478 45.66 8900 32.57 
Joint related signs and symptoms 12153 44.47 10691 39.12 
Dietary and nutritional therapies 11088 40.57 10941 40.04 
Non-site specific injuries NEC 10949 40.07 7931 29.02 
Dermatitis and eczema 10442 38.21 8736 31.97 
Lower respiratory tract and lung infections 10357 37.90 7734 28.30 
Lower respiratory tract infections NEC 10326 37.79 7709 28.21 
Reproductive organ and breast histopathology 
procedures 
9986 36.54 10502 38.43 
Pain and discomfort NEC 8849 32.38 7585 27.76 
Oral soft tissue infections 8693 31.81 8108 29.67 
Gastrointestinal and abdominal pains (excl oral 
and throat) 
8637 31.60 7805 28.56 
Asthenic conditions 8219 30.08 5825 21.32 
Neurological signs and symptoms NEC 7933 29.03 4404 16.12 
Skin structures and soft tissue infections 7823 28.63 5654 20.69 
Headaches NEC 7733 28.30 5677 20.77 
Cardiac signs and symptoms NEC 7544 27.61 5307 19.42 
Allergies to foods, food additives, drugs and 
other chemicals 
7499 27.44 6002 21.96 
Depressive disorders 7177 26.26 5660 20.71 
Urinary tract infections 7098 25.97 5133 18.78 
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls
Seizures and seizure disorders NEC 2638 9.65 11 0.04 
Mental retardations 199 0.73 8 0.03 
Withdrawal and rebound effects 46 0.17 5 0.02 
Disability issues 277 1.01 33 0.12 
Abnormal behaviour NEC 47 0.17 6 0.02 
Sodium imbalance 156 0.57 20 0.07 
Pervasive developmental disorders NEC 44 0.16 6 0.02 
Behaviour and socialisation disturbances 197 0.72 29 0.11 
Calcium metabolism disorders 35 0.13 6 0.02 
Cerebellar coordination and balance disturbances 50 0.18 8 0.03 
Therapeutic bladder catheterisation 109 0.40 20 0.07 
Lower respiratory tract inflammatory and 
immunologic conditions 
35 0.13 6 0.02 
Nervous system therapeutic procedures NEC 66 0.24 12 0.04 
Salivary gland disorders NEC 49 0.18 9 0.03 
Confusion and disorientation 179 0.66 38 0.14 
Cortical dysfunction NEC 199 0.73 43 0.16 
Thoracic cage fractures non-spinal (excl pathological) 32 0.12 7 0.03 
Thoracic cage fractures and dislocations 32 0.12 7 0.03 
Schizophrenia NEC 22 0.08 5 0.02 
Bipolar disorders 26 0.10 6 0.02 
Psychiatric elimination disorders 42 0.15 10 0.04 
Tremor (excl congenital) 223 0.82 57 0.21 
Nervous system haemorrhagic disorders 31 0.11 8 0.03 
Delusional symptoms 23 0.08 6 0.02 
Drug withdrawal therapies 33 0.12 9 0.03 
w
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls
Seizures and seizure disorders NEC 26225 95.96 279 1.02 
Cerebral disorders congenital 559 2.05 11 0.04 
Congenital and peripartum cerebral disorders 419 1.53 11 0.04 
Neonatal neurological system disorders NEC 271 0.99 8 0.03 
Nervous system neoplasms unspecified malignancy NEC 365 1.34 11 0.04 
Meningiomas benign 240 0.88 11 0.04 
Hydrocephalic conditions 345 1.26 18 0.07 
Mental retardations 1342 4.91 87 0.32 
Traumatic central nervous system haemorrhages 191 0.70 13 0.05 
Cerebrovascular embolism and thrombosis 59 0.22 5 0.02 
Developmental disorders cognitive 377 1.38 28 0.10 
Vascular anomalies congenital NEC 171 0.63 12 0.04 
Leukopenias NEC 69 0.25 5 0.02 
Paralysis and paresis (excl cranial nerve) 1458 5.34 114 0.42 
Encephalopathies NEC 154 0.56 12 0.04 
Congenital eye disorders NEC 137 0.50 11 0.04 
Disability issues 2277 8.33 212 0.78 
Pervasive developmental disorders NEC 495 1.81 44 0.16 
Nervous system haemorrhagic disorders 977 3.58 85 0.31 
Anterior pituitary hypofunction 86 0.31 8 0.03 
Cerebrovascular aneurysms and dissections 75 0.27 7 0.03 
Behaviour and socialisation disturbances 2575 9.42 308 1.13 
Inborn errors of amino acid metabolism 73 0.27 14 0.05 
Antidiuretic hormone related conditions 71 0.26 8 0.03 
Central nervous system aneurysms 61 0.22 7 0.03 
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls
Epilepsy 45635 54.95 0 0 
Convulsions 41078 49.46 9 0.01 
Other connective tissue disease 25108 30.23 16519 19.89 
Essential hypertension 24367 29.34 19961 24.04 
Immunizations and screening for infectious disease 23827 28.69 20398 24.56 
Disorders of lipid metabolism 23526 28.33 21045 25.34 
Other and unspecified lower respiratory disease 20413 24.58 12854 15.48 
Symptoms, signs and ill-defined conditions 20263 24.40 9946 11.98 
Other non-traumatic joint disorders 18437 22.20 12774 15.38 
Other skin disorders 18071 21.76 14957 18.01 
Other and unspecified upper respiratory infections 17051 20.53 14692 17.69 
Other nervous system symptoms and disorders 15474 18.63 4413 5.31 
Malaise and fatigue 13586 16.36 7983 9.61 
Other upper respiratory disease 12762 15.37 9794 11.79 
Abdominal pain 11910 14.34 7637 9.20 
Other eye disorders 11335 13.65 8142 9.80 
Other injuries and conditions due to external causes 11228 13.52 4945 5.95 
Depressive disorders 10907 13.13 4801 5.78 
Other central nervous system disorders 10826 13.04 2403 2.89 
Nonspecific chest pain 10769 12.97 6747 8.12 
Acute upper respiratory infections of multiple or 
unspecified sites 
10722 12.91 8206 9.88 
Other headache 10462 12.60 4132 4.98 
Other and unspecified gastrointestinal disorders 10127 12.19 5516 6.64 
Other bone disease and musculoskeletal deformities 9909 11.93 7073 8.52 
Other thyroid disorders 9886 11.90 6979 8.40 
w
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls 
Convulsions 76929 92.64 58 0.07 
Epilepsy 69782 84.03 0 0 
Other connective tissue disease 50298 60.57 36898 44.43 
Other and unspecified lower respiratory disease 46270 55.72 31447 37.87 
Other non-traumatic joint disorders 42216 50.84 31641 38.10 
Other skin disorders 41651 50.15 34760 41.86 
Other and unspecified upper respiratory infections 41109 49.50 36734 44.23 
Other nervous system symptoms and disorders 37912 45.65 11592 13.96 
Disorders of lipid metabolism 37001 44.56 32157 38.72 
Malaise and fatigue 35255 42.45 21419 25.79 
Essential hypertension 33858 40.77 27249 32.81 
Other upper respiratory disease 33727 40.61 26344 31.72 
Abdominal pain 32829 39.53 23175 27.91 
Other injuries and conditions due to external causes 32800 39.50 16637 20.03 
Nonspecific chest pain 31341 37.74 20177 24.30 
Acute upper respiratory infections of multiple or 
unspecified sites 
30716 36.99 24805 29.87 
Other headache 30126 36.28 13070 15.74 
Allergic reactions 28909 34.81 22971 27.66 
Other eye disorders 28567 34.40 21219 25.55 
Other and unspecified gastrointestinal disorders 27635 33.28 17061 20.54 
Superficial injury; contusion 26869 32.35 15552 18.73 
Other ear and sense organ disorders 26352 31.73 18559 22.35 
Other and unspecified circulatory disease 25911 31.20 15087 18.17 
Other central nervous system disorders 25633 30.87 4591 5.53 
Sprains and strains 25339 30.51 20144 24.26 
w
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls 
Odds Ratio 
(95% CI) 
Convulsions 41078 49.46 9 0.01 13688.40 
Intellectual disabilities 2010 2.42 17 0.02 143.10 
Cancer of brain and nervous system 1705 2.05 43 0.05 39.60 (29
Developmental disabilities 1312 1.58 45 0.05 36.20 
Other paralysis 3942 4.75 116 0.14 34.90 (28
Congenital hip dislocation 217 0.26 9 0.01 26.80 (13
Other nervous system congenital anomalies 864 1.04 34 0.04 25.40 
Learning disorders 1792 2.16 88 0.11 22.30 (17
Cerebrovascular anomalies 431 0.52 20 0.02 21.50 (13
Hemiplegia 1724 2.08 92 0.11 19.30 
Motor skill disorders 304 0.37 17 0.02 18.90 (11
Encephalitis (except that caused by TB or STD) 340 0.41 19 0.02 17.90 
Benign neoplasm of cerebral meninges 712 0.86 43 0.05 16.90 (12
Pervasive developmental disorders 1979 2.38 140 0.17 15.40 (12
Intrauterine hypoxia and birth asphyxia 72 0.09 5 0.01 14.40 (5
Intracranial hemorrhage 1237 1.49 92 0.11 13.90 (11
Respiratory distress syndrome 65 0.08 5 0.01 13.00(5.2
Congenital anomalies of skull and facial bones 150 0.18 13 0.02 11.50 (6
Aspiration pneumonitis; food/vomitus 952 1.15 85 0.10 11.30 (9
Spina bifida 215 0.26 20 0.02 10.80 (6
Congenital hip deformity 211 0.25 20 0.02 10.60 (6
Occlusion of cerebral arteries 4102 4.94 456 0.55 9.90 (9
Late effects of cerebrovascular disease 3354 4.04 375 0.45 9.80 (8
Other dependence on machines 59 0.07 6 0.01 9.80 (4
Acute but ill-defined cerebrovascular accident 3526 4.25 437 0.53 9.20 
w
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Comorbidity 
Number 
Cases 
Percent 
Cases 
Number 
Controls 
Percent 
Controls
Convulsions 76929 92.64 58 0.07 
Intellectual disabilities 3836 4.62 52 0.06 
Microcephalus 818 0.99 12 0.01 
Congenital hydrocephalus 780 0.94 17 0.02 
Cancer of brain and nervous system 3219 3.88 121 0.15 
Developmental disabilities 3129 3.77 153 0.18 
Other nervous system congenital anomalies 2545 3.06 119 0.14 
Other paralysis 6590 7.94 315 0.38 
Hemiplegia 4776 5.75 285 0.34 
Cerebrovascular anomalies 1506 1.81 87 0.10 
Intracranial hemorrhage 4660 5.61 307 0.37 
Learning disorders 4539 5.47 324 0.39 
Benign neoplasm of cerebral meninges 1530 1.84 98 0.12 
Coma; stupor; and brain damage 20114 24.22 1715 2.07 
Encephalitis (except that caused by TB or STD) 1264 1.52 80 0.10 
Motor skill disorders 1047 1.26 79 0.10 
Pervasive developmental disorders 2978 3.59 251 0.30 
Aspiration pneumonitis; food/vomitus 2675 3.22 218 0.26 
Occlusion of cerebral arteries 11582 13.95 1286 1.55 
Secondary malignancy of brain/spine 619 0.75 52 0.06 
Congenital hip dislocation 569 0.69 49 0.06 
Mental disorders due to general medical 
conditions not elsewhere classified 
2139 2.58 192 0.23 
Dissociative disorders 185 0.22 16 0.02 
Acute but ill-defined cerebrovascular accident 9617 11.58 1233 1.48 
Late effects of cerebrovascular disease 7766 9.35 967 1.16 
w
w
w
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Drug N (%) 
Anti-Epileptic Drugs 26584 (97.3) 
Anti-depressants 4806 (17.6) 
Valproic acid 9293 (34.0) 
Carbamazepine 8776 (32.1) 
Lamotrigine 5020 (18.4) 
Phenytoin 4757 (17.4) 
Levetiracetam 2977 (10.9) 
Phenobarbital 1645 (6.02) 
Clobazam 1161 (4.3) 
Topiramate 1133 (4.2) 
Gabapentin 784 (2.9) 
Clonazepam 733 (2.7) 
Primidone 570 (2.1) 
Pregabalin 507 (1.9) 
GPRD= General Practice Research Database. Note: the following anti-epileptic drugs were prescribed to 
<1% of the patients with epilepsy: zonisamide, oxcarbazepine, ethosuximide, lacosamide, vigabitrin, 
acetazolamide, rufinamide, tiagabine hydrochloride, paraldehyde, stiripentol, sultiame or mesuximide. No 
patients were prescribed beclamide, dipotassium clorazepate, eslicarbazepine acetate, or fosphenytoin 
sodium. 
Table 11. Prevalence of use of anti-convulsants and anti-depressants in epilepsy patients 
during the one-year period of observation from 01 Jan 2009 to 31 Dec 2009 in GPRD 
 
Drug Category N (%) 
Control of epilepsy 26595 (97.3) 
Neuropathic pain 14297 (52.3) 
Non-opioid analgesics 10861 (39.7) 
Antimanic drugs 8859 (32.4) 
Non-steroidal anti-inflammatory drugs 8249 (30.2) 
Opioid analgesics 6516 (23.8) 
Broad-spectrum penicillins 5763 (21.1) 
Statins 5530 (20.2) 
Urinary-tract infections 5308 (19.4) 
Proton pump inhibitors 5244 (19.2) 
Topical corticosteroids 4856 (17.8) 
Antiplatelet drugs 4587 (16.8) 
Selective beta-2-agonists 3983 (14.6) 
Anxiolytics 3684 (13.5) 
Emollient skin preparations 3535 (12.9) 
Osmotic laxatives 3362 (12.3) 
Hypnotics 3345 (12.2) 
Angiotensin-converting enzyme inhibitors 3274 (12.0) 
Skeletal muscle relaxants 3064 (11.2) 
Anxiolytics and neuroleptics (in anaesthesia) 3041 (11.1) 
Selective serotonin re-uptake inhibitors 2886 (10.6) 
Prophylaxis of migraine 2863 (10.5) 
Corticosteroids (inhaled for respiratory conditions) 2859 (10.5) 
Beta-adrenoceptor blocking drugs 2819 (10.3) 
Drugs used in nausea and vertigo 2747 (10.1) 
BNF= British National Formulary; GPRD= General Practice Research Database 
Table 12. Prevalence of use of the top 25 most frequent medications in epilepsy patients during 
the one-year period of observation from 01 Jan 2009 to 31 Dec 2009, by BNF Category in GPRD 
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Drug N (%) 
Anti-depressants 10378 (22.1) 
Anticonvulsants- antiepileptics 35543 (75.8) 
Lamotrigine 7157 (15.3) 
Phenytoin 6877 (14.7) 
Carbamazepine 5549 (11.8) 
Topiramate 3976 (8.5) 
Clonazepam 2973 (6.3) 
Gabapentin 2279 (4.9) 
Phenobarbital 2070 (4.4) 
Valproate 503 (1.1) 
Ethosuximide 428 (0.9) 
Methsuximide 16 (0.03) 
IHCIS= Integrated Healthcare Information Services 
Table 13. Prevalence of use of anti-convulsants and anti-depressants in epilepsy patients 
during the one-year period of observation from 01 Jan 2009 to 31 Dec 2009 in IHCIS 
 
Drug Category N (%) 
Seizure disorders 34723 (74.0) 
Codeine & Comb, Non-Inj 10742 (22.9) 
Extended spectrum macroli 8784 (18.7) 
Benzodiazepines 7715 (16.5) 
SSRI 7037 (15.0) 
HMG-COA reductase inhibitors 6693 (14.3) 
Aminopenicillins 6304 (13.4) 
Hormones, Cort plain, oral 5941 (12.7) 
Cephalosporins & related 5829 (12.4) 
Proton pump inhibitors 5642 (12.0) 
Anti-arthritis, plain 5627 (12.0) 
Quinolones, systemic 5525 (11.8) 
Beta blockers 4332 (9.2) 
Steroid, inhaled nasal 4244 (9.1) 
B-lactam, increased activity 4212 (9.0) 
Mus relx, non-surg,W/O ANA 4150 (8.9) 
Hormones,Cort plain, derm 3732 (8.0) 
Thyroid hormone, synth 3616 (7.7) 
ACE Inhib, alone 3579 (7.6) 
Beta agonists, aerosol 3522 (7.5) 
Antivirals, other 3482 (7.4) 
Sulfa & Trimeth comb 3020 (6.4) 
Calcium blockers 2690 (5.7) 
Antipsychotics, other 2638 (5.6) 
Analeptics 2493 (5.3) 
Table 14. Prevalence of use of the top 25 most frequent medications in epilepsy patients 
during the one-year period of observation from 01 Jan 2009 to 31 Dec 2009, by Universal 
System Classification Fourth Level in IHCIS 
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4. Discussion 
Electronic medical record systems provide an opportunity to identify treatment patterns and 
comorbidities in a large diagnosed disease population. They also allow for comparisons 
between the relative prevalence estimates of various comorbidities within the same data 
source. The comorbidities were ranked by how prevalent they were in epilepsy cases, and 
then by the ORs comparing cases to controls. The conditions with the highest ORs have the 
strongest associations with epilepsy compared to matched controls, therefore these findings 
may be hypothesis-generating for conditions related to epilepsy, though temporality cannot 
be established in this cross-sectional study. For instance, these can be tested as risk factors 
for epilepsy; conversely, epilepsy can be examined as a risk factor for these associated 
conditions. 
The definition of both cases and controls requires that patients are registered throughout the 
full lead-in and analysis periods. The lead-in period is used to identify existing epilepsy 
patients to ensure that all cases have epilepsy prior to the start of the observation period. 
This ensures that patients are "at risk" of receiving management for epilepsy throughout the 
observation period when the patient's status is being assessed. This cross sectional 
approach, based on a set calendar index date, means there is no restriction of the duration of 
epilepsy prior to the start of observation, and the population is likely to contain both 
prevalent and newly-diagnosed epilepsy cases. The use of an index date tied to an 
individual patient (such as their first diagnosis on a database) is another possible approach, 
which is more tailored incident cases (or patients at an earlier stage of the disease) and 
historical rather than recent management patterns. 
Diagnosed prevalence rates were similar in a US insurance claims database (0.5%) and a UK 
general practice-based electronic medical record system (0.8%), although peak age 
prevalence differed, likely based on the patient populations covered by these systems. The 
IHCIS system under-represents the elderly population, because it mainly consists of the 
employed, insured population. These prevalence estimates are similar to those reported in 
the literature for studies with records-based methodology, ranging from 3 to 8 per 1000 
persons (Banerjee et al., 2009). 
Many diagnosed comorbidities, including psychiatric and neurological comorbidities, were 
more prevalent in the patients with epilepsy compared to matched controls. A previous 
study in the GPRD also reported that many conditions were associated with epilepsy 
(Gaitatzis, 2004). The current study supports the evidence that the burden of epilepsy along 
with its comorbidities is high compared to the general population. 
Major depression is a common co-morbidity of epilepsy with at least 20% of epilepsy 
patients experiencing mild to severe depressive symptoms (O’Donoghue et al., 1999; 
Mendez et al., 1986; Hermann et al., 1986; Baker et al., 1996; Cramer et al., 2004; Jacoby et 
al., 1996; Boylan et al., 2004; Beghi et al., 2002). In the current study, 29% of patients with 
epilepsy in the GPRD (OR= 1.5, 95%CI: 1.4-1.5), and 24% of patients with epilepsy in the 
IHCIS (OR=2.6, 95%CI: 2.5-2.7) had a diagnosis of depression in the analysis period or 
before. Studies using structured psychiatric interviews in epilepsy clinics, likely to 
represent more severe epilepsy patients, have reported a prevalence of major depression 
of up to 55% (Mendez et al., 1996). However, the cross-sectional nature of most studies 
prevents inferences concerning the temporal order of disease development. When 
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longitudinal analyses have been completed a history of major depression has been 
associated with an increased risk for incident epilepsy and first unprovoked seizure 
(Nilsson et al., 2003; Forsgren & Nystrom 1990; Hesdorffer et al., 2006; Hesdorffer et al., 
2000). 
Certain epilepsy types may be at increased risk of depression: the mean estimated lifetime 
prevalence of depression is 30% for patients with temporal lobe epilepsy and refractory 
epilepsy with corresponding risks in the general population of between 6% and 17% 
(Glosser et al., 2000). Studies have consistently identified co-morbid depression as a 
powerful predictor of poor health related quality of life in epilepsy patients even after 
adjustment for seizure frequency and severity (Kanner, 2009). Depression is also a strong 
predictor for increased suicidality among epilepsy patients (Kanner, 2009). 
The prevalence of anxiety disorders is consistently higher (approximately twofold increased 
risk) among epilepsy patients than the general population. In the current study, 21% of 
patients with epilepsy in the GPRD (OR= 1.4, 95%CI: 1.3-1.5), and 26% of patients with 
epilepsy in the IHCIS (OR=2.1, 95%CI: 2.1-2.2) had a diagnosis of anxiety in the analysis 
period or before. Studies using a range of disease measurement scales, and capturing 
patients mainly through cross sectional health surveys, have reported point prevalence 
estimates in epilepsy patients of 11% to 39% (Gaitatzis et al., 2004; Tellez-Zenteno et al., 
2007; Edeh & Toone, 1987; Stirne et al., 2005; Kobau et al., 2006). The variation is likely to 
reflect the selection of different subsets of the epilepsy population with higher prevalence 
estimates observed among patients with temporal lobe epilepsy. 
The prevalence of psychoses in epilepsy, as reported from population-based studies, ranges 
from 2% to 7% (Gaitatzis et al., 2004). The prevalence varies by epilepsy type with estimates 
of 10% to 19% reported among individuals with temporal lobe epilepsy, nearly double the 
risk associated with generalised epilepsy, though larger differences have been reported in 
older studies (Gaitatzis et al., 2004; Shukla et al., 1979). Gender differences have also been 
reported with females at an increased risk of psychoses. An Icelandic study reported 6% 
prevalence in males with epilepsy versus 9% in females (Gudmundsson, 1966). In the 
current study, 9% of patients with epilepsy in the IHCIS (OR=9.7, 95%CI: 9.0-10.4) had a 
diagnosis of psychosis in the analysis period or before. 
The incidence of psychoses is reported to be 3 to 12 times higher in epilepsy patients than 
the general population. The range again depends on the epilepsy population sampled 
(seizure type and severity) as well as the instrument used to diagnose psychosis (Bredkjaer 
et al., 1998; Torta & Keller, 1999).  Patients undergoing epilepsy surgery are at particular risk 
of developing psychoses for the first time. Interictal psychoses can develop in 3% to 12% of 
patients following anterior temporal lobectomy and seizure-related psychoses can affect 1% 
to 13% of patients (Gaitatzis et al., 2004; Gaitatzis et al., 2004 (2)). 
Studies concentrating solely on schizophrenia have reported prevalence estimates of 4% to 
18% among patients with epilepsy (the majority suffering from temporal lobe epilepsy) 
(Gaitatzis et al., 2004; Gaitatzis et al., 2004 (2)). The expected prevalence of schizophrenia in 
the general population is 1% (Toone, 2000). Patients with schizophrenia are also at an 
increased risk of seizures related to the condition itself and to exposure to psychotropic 
medications that lower seizure threshold (e.g. clozapine) (Torta & Keller, 1999). In the 
current study, 1% of patients with epilepsy in the GPRD (OR=2.8, 95%CI: 2.5-3.1) had a 
diagnosis of schizophrenia in the analysis period or before. 
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Suicide is a much discussed cause of death in epilepsy patients, especially with the recent 
analysis by the US Food and Drug Administration in 2008 that showed an association 
between AEDs and suicidality in pooled clinical trials. Population-based studies report that 
between 0% and 9% (Sweden and Iceland, respectively) of deaths among patients with 
epilepsy result from suicide (Tomson et al., 2004). However it is not clear whether epilepsy 
or its treatment increases the risk of suicide: suicide attempt has been associated with an 
increased risk for developing epilepsy indicating the association could represent the 
recurrence, post epilepsy diagnosis, of an underlying suicidality risk 74. The GPRD and 
IHCIS results indicate an association between epilepsy diagnosis and suicidality, with an 
OR of 2.8 (95% CI: 2.5-3.1) in GPRD and 5.5 (95% CI: 5.2-6.0) in IHCIS for during or ever 
before the analysis period. 
The reported prevalence of migraine among epilepsy patients ranges from 8% to 23% 
(Marks & Ehrenberg, 1993) compared with 12% in the general population (Lipton et al., 
2007). While the majority of studies report the risk of migraine to be two-fold greater among 
epilepsy patients (Lipton et al., 1994), two studies failed to confirm this association (Karaali-
Savrun et al., 2002; Nuyen et al., 2006). This discordance is most likely due to differences in 
migraine definition and the absence of well defined control groups in some studies. Recent 
studies indicate that the association is primarily with migraine with aura, though the 
absolute prevalence of migraine with aura among epilepsy patients has yet to be reported 
(Piccinelli et al., 2006).  
The IHCIS and GPRD database studies supported a positive association between epilepsy 
and migraine. A history of diagnosed migraine was present in 16% of epilepsy cases and 5% 
of controls in the IHCIS database study (OR = 3.7, 95% CI: 3.6-3.8). In the GPRD database, 
9% of cases and 7% of controls had a history of diagnosed migraine (OR= 1.3, 95% CI: 1.3-
1.4). The differential prevalences between the databases likely reflect between-country 
differences in diagnostics, awareness and treatment of migraine. 
The current medication data was only reported for the patients with epilepsy to determine 
the most commonly used medications among patients with epilepsy. The most common 
AEDs varied between the US and UK databases. This is likely due to different treatment 
patterns and guidelines in the two countries. It has previously been shown that there is an 
association between the first AED prescribed after diagnosis of and history of psychiatric 
disorders, including depression and bipolar disorder, and the differential prescribing varied 
between the US and UK (Ishihara et al., 2010). One potential use of these data is to 
characterise polypharmacy patterns to inform potential drug interaction studies. Since the 
majority of patients are prescribed AEDs, the list identifies other medication types that are 
commonly used among the epilepsy patients. 
The study should be interpreted in the context of its strengths and potential limitations. The 
strengths of the study include the large sizes of the databases, and the availability of 
detailed diagnosis and medication records. The GPRD is representative of the general 
population of the UK, and the IHCIS is representative of the US insured population. The 
IHCIS database is a large sample of people in the US covered by private insurance plans. 
Therefore results of this study may not be representative of US patients who receive 
healthcare through government organizations (e.g., Medicare, Medicaid) or who lack health 
insurance; for instance, these patients may be more likely to receive generic or older AEDs. 
In both databases, only diagnosed diseases are recorded, and therefore patients had to 
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present to healthcare to be diagnosed with conditions or prescribed medications.  There is a 
possibility of confounding by consultation frequency because patients with epilepsy or other 
chronic medical conditions will be more likely to be seen by healthcare providers compared 
to the general population.  
The results of this study can be used to generate hypotheses about which medical conditions 
may be associated with epilepsy (either as risk factors for epilepsy, or resulting from 
epilepsy).  Understanding the comorbidities and medication patterns in epilepsy also 
informs the effects of eligibility criteria on clinical trial recruitment, and facilitates 
assessments of potential safety signals that may arise in clinical trials (e.g. if a conditions is 
more common within the disease population at baseline, then this should be taken into 
account in evaluating whether exposure to a medication is associated with that condition). 
5. Conclusion 
In conclusion, psychiatric, neurological and other comorbidities are more common in 
patients with epilepsy, compared to age-, sex-matched controls. The results of this study 
provide hypotheses about conditions which may be associated with epilepsy, and these may 
be the subject for further investigation. 
Among patients with epilepsy, the most commonly prescribed medications varied between 
the UK and US. Two of the older AEDs, valproate and carbamazepine, were the most 
commonly prescribed AEDs in 2009 amongst epilepsy patients in GPRD. Lamotrigine and 
phenytoin were the most commonly prescribed AEDs to patients with epilepsy in 2009 
within IHCIS.  
The most commonly prescribed medications among the epilepsy patient population, aside 
from AEDs, included analgesics, non-steroidal anti-inflammatory drugs, extended spectrum 
macroli (anti-biotics), selective serotonin reuptake inhibitors, and statins. The list of 
commonly prescribed medications in the epilepsy patient population can give an indication 
as to which drugs to consider for possible drug-drug interactions. 
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